US12612389B2 - Anticancer Benzofuran Derivative Patent Grant
Summary
The USPTO granted US Patent 12612389B2 to the Korea Research Institute of Bioscience and Biotechnology for a benzofuran-based N-acylhydrazone derivative demonstrating anticancer activity. Filed July 14, 2020 under application number 17627547, the patent contains 19 claims under CPC classification C07D 405/12. The invention is characterized as having low toxicity and excellent solubility alongside its anticancer efficacy, making it suitable for pharmaceutical compositions treating cell proliferative disorders and various cancers.
“A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
US Patent 12612389B2 has been granted for a benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising the same. The patent, assigned to the Korea Research Institute of Bioscience and Biotechnology, protects a compound exhibiting anticancer effects with low toxicity and enhanced solubility. The filing date was July 14, 2020, with the grant effective April 28, 2026.
Affected parties include the assignee, Korea Research Institute of Bioscience and Biotechnology, which now holds exclusive rights to the claimed invention. Inventors Bo Yeon Kim, Nak Kyun Soung, Mija Ahn, Ho Jin Han, In Ja Ryoo, and Joonsung Hwang are credited for the development. No immediate compliance obligations arise for third parties from this grant.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same
Grant US12612389B2 Kind: B2 Apr 28, 2026
Assignee
Korea Research Institute of Bioscience and Biotechnology
Inventors
Bo Yeon Kim, Nak Kyun Soung, Mija Ahn, Ho Jin Han, In Ja Ryoo, Joonsung Hwang
Abstract
A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.
CPC Classifications
C07D 405/12
Filing Date
2020-07-14
Application No.
17627547
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.